Market Place
Sourcing Support
BeiGene co-founder snag $200M for age-related biotech, with ARCH jumping in
02 Aug 2022 //
ENDPTS
Viela Bio Biologic Uplizna (Inebilizumab) Receives Approval in Europe
19 May 2022 //
EMA
Compliance officer profited off Horizon-Viela and Jazz-GW deals
01 Oct 2021 //
FIERCEPHARMA
Viela Bio Announces Additional Positive Results with UPLIZNA®
26 Feb 2021 //
BIOSPACE
Viela Bio Announces Additional Positive Results with UPLIZNA®
25 Feb 2021 //
GLOBENEWSWIRE
Horizon Therapeutics to Purchase Viela Bio for $3.1 Billion
03 Feb 2021 //
BLOOMBERG
Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting
03 Sep 2020 //
GLOBENEWSWIRE
AZ spinoff faces tough task launching its first drug
15 Jun 2020 //
FIERCE PHARMA
Viela Bio`s Uplizna (Inebilizumab ) Receives Supplemental Approval in US
13 Jun 2020 //
FDA
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon)
11 Jun 2020 //
GLOBENEWSWIRE
Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734
13 May 2020 //
PIPELINEREVIEW
Viela Bio to develop autoimmune drug for nine Asian regions
10 Oct 2019 //
BIOSPECTRUM ASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.